iPSC-Derived BCMA-Specific T Cells Overcoming Exhaustion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies, such as CAR-T cell therapy, face challenges with T cell exhaustion and muted functional anti-tumor responses, leading to limited clinical efficacy and off-tumor toxicity.
Innovation Solution
The development of induced pluripotent stem cells (iPSCs) specific to B-Cell Maturation Antigen (BCMA) that can re-differentiate into rejuvenated antigen-specific memory CD8+ cytotoxic T lymphocytes (CTL), overcoming T cell exhaustion and enhancing long-term cytotoxicity against tumor cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CAR-T cell therapy is used to treat cancer, then T cell anti-tumor response is activated, but T cell exhaustion occurs leading to limited clinical efficacy
Solution Approach 1:
The invention segments the T cell therapy process into two distinct stages: (1) generation of antigen-specific T cells from iPSCs with desired specificity, and (2) re-differentiation of these T cells from an exhausted state to a functional memory phenotype. This segmentation allows independent optimization of each stage to overcome T cell exhaustion and improve clinical efficacy
Solution Approach 2:
The invention performs preliminary action by first generating antigen-specific T cells from iPSCs before they undergo exhaustion, then preserving them in a controlled state, and finally re-differentiating them to a functional memory phenotype before administration. This preliminary preparation ensures the T cells maintain high functionality and avoid exhaustion upon re-differentiation
2Strength
If T cells are expanded and activated to enhance anti-tumor response, then cytotoxicity increases, but off-tumor toxicity occurs
Solution Approach 1:
The invention applies local quality by engineering T cells with antigen-specific receptors (TCR or CAR) that provide localized specificity to tumor antigens. The T cells are equipped with molecular structures that enable them to distinguish tumor cells from normal cells based on antigen presence, thereby enhancing cytotoxicity toward tumors while minimizing off-tumor toxicity
Solution Approach 2:
The invention incorporates feedback mechanisms through antigen-specific recognition systems where T cells continuously monitor for the presence of target antigens on tumor cells. The cytotoxic activation is feedback-controlled by antigen binding events, ensuring T cells only exert cytotoxicity when and where tumor antigens are detected, thus avoiding off-tumor toxicity
3Measurement precision
If iPSCs are reprogrammed to generate antigen-specific T cells, then T cell specificity is improved, but reprogramming complexity increases
Solution Approach 1:
The invention uses intermediary elements (reprogramming factors such as Oct4, Sox2, Klf4, and c-Myc) that mediate the transformation of somatic cells into iPSCs. These intermediary factors facilitate controlled reprogramming with desired antigen specificity while managing the complexity of the reprogramming process through standardized molecular tools and protocols
4Strength
If T cells are maintained in activated state to enhance anti-tumor activity, then cytotoxic function improves, but T cell exhaustion accelerates
Solution Approach 1:
The invention applies dynamics by enabling T cells to transition between different functional states: from an activated high-cytotoxicity state to a memory phenotype with extended lifespan. This dynamic state transformation allows T cells to exert strong anti-tumor activity when needed while preserving long-term functionality and avoiding exhaustion through state plasticity
Data Source
AI summary
Aspects of the invention are drawn to induced pluripotent stem cells (iPSC) and re-differentiated T cells from iPSC, related compositions, and methods of using the same.